Last update: Jan. 24, 2017

Flavoxate Hydrochloride

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Anticholinergic and smooth-muscle relaxant with antimuscarinic action which is used to relieve spasticity, inflammation, pain and incontinence of the urine bladder tract.

At latest update relevant published data on its excretion into breast milk were not found.

The antimuscarinic effect may reduce milk production (De Martino 1980, Bizarro 1980), albeit only during the first weeks postpartum.

Side effects occur very rarely with a rather low risk during lactation when timely used. Monitoring of milk production and anticholinergic symptoms in the infant such as irritability, nausea or constipation would be desirable.

Until more published data on this drug related to breastfeeding is available, an alternative with a known pharmacokinetic profile that should appear safer while breastfeeding (higher protein-binding capacity, lower half-life span and lower oral bioavailability) may be preferable, especially during the neonatal period and in case of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Flavoxate Hydrochloride in other languages or writings:

Group

Flavoxate Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Flavoxate Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Bioavailability 100 %
Molecular weight 428 daltons
VD 2,9 l/Kg
Tmax 1 - 2 hours
T1/2 3,5 - 10 hours

References

  1. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003 Abstract
  2. Bizzarro A, Iannucci F, Tolino A, Soricelli A, Guarino G, Verdoliva A. Inhibiting effect of atropine on prolactin blood levels after stimulation with TRH. Clin Exp Obstet Gynecol. 1980 Abstract
  3. De Martino F, De Matteo A, L'Abbate V, Soricelli A, Fontana A, Petrenga E, Cesarone M. [Inhibitory effects of atropine on serum prolactin levels after TRH stimulation]. Boll Soc Ital Biol Sper. 1980 Abstract
  4. Bertoli M, Conti F, Conti M, Cova A, Setnikar I. Pharmacokinetics of Flavoxate in man. Pharmacol Res Commun. 1976 Abstract

Total visits

13,498

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM